Benitec Biopharma is a clinical-stage biotechnology company. Co. focuses on the development of genetic medicines. Co.'s proprietary platform, DNA-directed RNA interference, or ddRNAi, combines RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Co.'s pipeline includes: BB-301, which is for the treatment of oculopharyngeal muscular dystrophy; BB-103, which is for the treatment of Hepatitis B; and TT-034, which is for the treatment of Hepatitis C. Co. has licensed its ddRNAi technology to companies who are developing therapeutic programs in other disease areas, such as cancer immunotherapy. The BNTC stock yearly return is shown above.
The yearly return on the BNTC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BNTC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|